chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Periorbital swelling
Clinical narrative: Narrative: Pt reported swelling around they eyes 4-5 hrs after receiving first dose of Pfizer COVID-19 vaccine. Pt stated that she took some antihistamines (Chlorpheniramine) and it helped. Swelling subsided the next morning. Has a history of swelling around the eyes after taking NSAIDS.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event
Clinical narrative: Narrative: 45 yo female Veteran reportedly developed a rash following the first dose of the PFIZER COVID vaccine. There are no details regarding the treatment  of her reaction or need for continued treatment. Only the information for her  second vaccine, which she received on 4/27/21, is in; no reactions  documented after the 2nd dose.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: Narrative:  Per Immunization Registry information, patient received two different COVID-19 vaccines (Pfizer 3/25 and Moderna 4/22). There were both administered outside the facility. Detected by nursing staff on review of vaccine registry. Unknown if patient had any adverse reaction to vaccine as these were not administered on site.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Muscle fatigue, Myalgia, Nausea, Vomiting
Clinical narrative: Narrative: Patient reported nausea and vomiting and all over muscle  fatigue/myalgias starting 3 days after vaccine and lasting aprox. 24 hours.  Patient self-treated with acetaminophen and recovered completely.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Dizziness, Dyspnoea, Paraesthesia oral, Throat tightness
Clinical narrative: Narrative: About 25 minutes after receiving 2nd dose of Pfizer COVID-19 vaccine, Patient began feeling tingling around the lips/tongue, tightness in her throat, shortness of breath, and lightheadedness. Pt then began complaining of fire-like sensation in while body. Provider called to evaluate and medicated with epinephrine which reduced severity of symptoms. EMS activated and pt sent out via ambulance.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Throat irritation
Clinical narrative: Narrative:  39-year old male patient experienced scratchy and itchy throat and pruritus without rash after receiving second Pfizer vaccine. No chest pain, shortness of breath, nausea, vomiting, diarrhea. Given 10mg cetirizine in the clinic and then sent to ED. Discharged from home from ED with prednisone, diphenhydramine and famotidine.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Bradycardia, Death, Hypervolaemia, Hyponatraemia, Life support
Clinical narrative: Narrative: 76 y/o M with obesity, OSA, HTN, DM2, CAD (non-obstructive on cath 2010), suspected HFpEF, prior VTE (bilateral PE, on chronic warfarin), localized prostate CA (s/p XRT and ADT complicated by radiation cystitis and urethral stricture s/p suprapubic tube), and recent diagnosis of urothelial carcinoma complicated by bilateral hydroureter admitted with acute on chronic symptomatic hyponatremia and volume overload. On 05/09 he was found to be increasingly bradycardic and was unresponsive on assessment. He underwent ACLS but Pt passed. Per death note, no clear etiology of death, greatest concern for cardiac related given initial rhythm VT. Pt received 2nd dose of Pfizer vaccine 2 months ago.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Unresponsive to stimuli, Ventricular tachycardia
Clinical narrative: Narrative: 76 y/o M with obesity, OSA, HTN, DM2, CAD (non-obstructive on cath 2010), suspected HFpEF, prior VTE (bilateral PE, on chronic warfarin), localized prostate CA (s/p XRT and ADT complicated by radiation cystitis and urethral stricture s/p suprapubic tube), and recent diagnosis of urothelial carcinoma complicated by bilateral hydroureter admitted with acute on chronic symptomatic hyponatremia and volume overload. On 05/09 he was found to be increasingly bradycardic and was unresponsive on assessment. He underwent ACLS but Pt passed. Per death note, no clear etiology of death, greatest concern for cardiac related given initial rhythm VT. Pt received 2nd dose of Pfizer vaccine 2 months ago.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pyrexia
Clinical narrative: Narrative: Patient contacted provider on 3/31/21 indicating he had received his second COVID-19 Moderna vaccine on 3/29/21 and was experiencing fever/chills and treating with ibuprofen and acetaminophen alternating between the medications. Was followed-up with and indicated the fever had broken and he was feeling much better, with only slight fatigue noted.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Nasopharyngitis, Oropharyngeal pain, Productive cough, Pruritus
Clinical narrative: Narrative:  Pt is a 38 y/o female with PMH significant for migraine, sleep disorder, obesity, back pain, major depression/personality disorder, GERD, bipolar disorder, and asthma. Pt received COVID-19 vaccine #1 on 3/25/21 and COVID-19 Vaccine #2 on 4/15/2021. Per 4/21/2021 Primary Care Secure Messaging, pt reports c/o rash down her arms, neck, and left check bone describing sxs similar to exposure to poison ivy after receiving second COVID vaccine. Pt also informed 1 week after receiving her first COVID vaccine, she experienced a rash all over her arm. Per 4/22/2021 sameday clinic note, pt currently takes loratadine for allergies. She took Benadryl for pruritis and OTC hydrocortisone cream to help with sxs from rash in which she noted some improvement but did not completely resolve rash. Pt was prescribed hydroxyzine 25 mg TID prn for pruritis and triamcinolone 0.1% cream BID. Per 4/29/2021 nursing outpt tele note, pt reports cold sxs of productive cough, headache, sinus and congestion, slight fever, with sore throat/runny nose, however, pt does not think this is related to the COVID vaccination given son and husband also are experiencing similar sxs. Per pt, body rash was resolved a few days before cold symptoms started. Upon chart review, no other sxs related to rash noted.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, Rash, Respiratory tract congestion, Rhinorrhoea, Sinus disorder
Clinical narrative: Narrative:  Pt is a 38 y/o female with PMH significant for migraine, sleep disorder, obesity, back pain, major depression/personality disorder, GERD, bipolar disorder, and asthma. Pt received COVID-19 vaccine #1 on 3/25/21 and COVID-19 Vaccine #2 on 4/15/2021. Per 4/21/2021 Primary Care Secure Messaging, pt reports c/o rash down her arms, neck, and left check bone describing sxs similar to exposure to poison ivy after receiving second COVID vaccine. Pt also informed 1 week after receiving her first COVID vaccine, she experienced a rash all over her arm. Per 4/22/2021 sameday clinic note, pt currently takes loratadine for allergies. She took Benadryl for pruritis and OTC hydrocortisone cream to help with sxs from rash in which she noted some improvement but did not completely resolve rash. Pt was prescribed hydroxyzine 25 mg TID prn for pruritis and triamcinolone 0.1% cream BID. Per 4/29/2021 nursing outpt tele note, pt reports cold sxs of productive cough, headache, sinus and congestion, slight fever, with sore throat/runny nose, however, pt does not think this is related to the COVID vaccination given son and husband also are experiencing similar sxs. Per pt, body rash was resolved a few days before cold symptoms started. Upon chart review, no other sxs related to rash noted.
Age: 99.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Bradycardia, Cardiac arrest, Cardio-respiratory arrest, Cardioversion
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for tobacco use, aortic aneurysm, chronic obstructive lung disease, advanced age. Pt presented to ED on 5/21/21 with a chief complaint of generalized weakness and lost of appetite. Was found to have bacterial pneumonia without respiratory failure, suspected dehydration. On 5/23 patient was hypotensive, tachycardia, and in septic shock. Went bradycardic and asystole, when code blue called. The code was called off by family. Pt was defibrillated two times.
Age: 99.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Decreased appetite, Dehydration, Hypotension, Pneumonia bacterial
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for tobacco use, aortic aneurysm, chronic obstructive lung disease, advanced age. Pt presented to ED on 5/21/21 with a chief complaint of generalized weakness and lost of appetite. Was found to have bacterial pneumonia without respiratory failure, suspected dehydration. On 5/23 patient was hypotensive, tachycardia, and in septic shock. Went bradycardic and asystole, when code blue called. The code was called off by family. Pt was defibrillated two times.
Age: 99.0
Sex: M
Vaccine: COVID19
Symptoms: Septic shock, Tachycardia
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for tobacco use, aortic aneurysm, chronic obstructive lung disease, advanced age. Pt presented to ED on 5/21/21 with a chief complaint of generalized weakness and lost of appetite. Was found to have bacterial pneumonia without respiratory failure, suspected dehydration. On 5/23 patient was hypotensive, tachycardia, and in septic shock. Went bradycardic and asystole, when code blue called. The code was called off by family. Pt was defibrillated two times.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Dyskinesia
Clinical narrative: Narrative: Patient was also newly started on a drug known to cause dyskinesia (droxidopa) which has been already reported. Due to timing of the vaccine and the drug starting, it is difficult to confirm if it was due to the second COVID vaccine dose or the medications.
Age: 97.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Pleural effusion
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for CKD stage 4, HTN, CHF, Atrial fibrillation, gout, advanced age. No information regarding death. Was evaluated for pleural effusion in April by pulmonary but was chosen for a conservative management.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Echocardiogram, Electrocardiogram ambulatory, Palpitations, Tremor
Clinical narrative: Narrative: Mr is a 76yo male with a PMH significant for HTN, GERD,  PTSD who called PCP with complaints of hand tremor and "pounding" of heart which he states began 2-3 days after receiving his second dose of COVID-19 vaccine on 4/9 and has persisted. PCP recommends neuro follow up along with Holter monitor and Echo. The issue is likely not secondary to COVID-19 vaccine, per PCP.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Alanine aminotransferase increased, Anion gap, Aspartate aminotransferase increased, Atrial fibrillation, Blood bilirubin increased
Clinical narrative: Narrative:  2-16-2021 admitted with sepsis, pyelonephritis and "HAGMA with lactic acidosis". WBC 2.8K, AST 332, ALT 196, T bili 1.8, gap 1.8, Lactic acidosis" but no value seen on note. CT abd shows bilateral perinephric stranding and fluid. and mild adynamic ileus. admitted to ICU. vitals: 39.2C, HR 107, resps 19, BP 114/58, sat 96%. "awake but somnolent. cooperative, ill appearing....". not requiring vasopressors, continuing with IV fluids and trending lactate. COVID test pending. Discharged 2/23- 3 days in ICU and 5 days on the floor Diagnosis: PATIENT WITH SEVERE SEPSIS SECONDARY TO ACUTE PYELONEPHRITIS. WAS ADMITTED TO HOSPITAL HE HAD SEPSIS SECONDARY TO  PYELONEPHRITIS ,HAGMA WITH LACTIC ACIDOSIS , HE HAD PROFOUND INTRAVASCULAR VOLUME DEPLETION,ELEVATED LIVER ENZYMES PAROXYSMAL ATRIAL FIBRILLATION , THROMBOCYTOPENIA CHRONIC HYPERTENSION, DM TYPE 2 .PATIENT WITH LIFE ORGAN SYSTEM THREATENING CONDITION WHICH PATIENT WAS AT HIGH RISK OF DECOMPENSATION .EMPHYSEMATPUS CYSTITIS MILD ADYNAMIC ILEUS. Unable to review chart notes from patient's stay at hospital. Nothing scanned in to chart.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Blood lactic acid, Brief resolved unexplained event, Computerised tomogram abdomen abnormal, Emphysematous cystitis, General physical condition abnormal
Clinical narrative: Narrative:  2-16-2021 admitted with sepsis, pyelonephritis and "HAGMA with lactic acidosis". WBC 2.8K, AST 332, ALT 196, T bili 1.8, gap 1.8, Lactic acidosis" but no value seen on note. CT abd shows bilateral perinephric stranding and fluid. and mild adynamic ileus. admitted to ICU. vitals: 39.2C, HR 107, resps 19, BP 114/58, sat 96%. "awake but somnolent. cooperative, ill appearing....". not requiring vasopressors, continuing with IV fluids and trending lactate. COVID test pending. Discharged 2/23- 3 days in ICU and 5 days on the floor Diagnosis: PATIENT WITH SEVERE SEPSIS SECONDARY TO ACUTE PYELONEPHRITIS. WAS ADMITTED TO HOSPITAL HE HAD SEPSIS SECONDARY TO  PYELONEPHRITIS ,HAGMA WITH LACTIC ACIDOSIS , HE HAD PROFOUND INTRAVASCULAR VOLUME DEPLETION,ELEVATED LIVER ENZYMES PAROXYSMAL ATRIAL FIBRILLATION , THROMBOCYTOPENIA CHRONIC HYPERTENSION, DM TYPE 2 .PATIENT WITH LIFE ORGAN SYSTEM THREATENING CONDITION WHICH PATIENT WAS AT HIGH RISK OF DECOMPENSATION .EMPHYSEMATPUS CYSTITIS MILD ADYNAMIC ILEUS. Unable to review chart notes from patient's stay at hospital. Nothing scanned in to chart.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Hepatic enzyme increased, Hypertension, Hypovolaemia, Ileus paralytic, Intensive care
Clinical narrative: Narrative:  2-16-2021 admitted with sepsis, pyelonephritis and "HAGMA with lactic acidosis". WBC 2.8K, AST 332, ALT 196, T bili 1.8, gap 1.8, Lactic acidosis" but no value seen on note. CT abd shows bilateral perinephric stranding and fluid. and mild adynamic ileus. admitted to ICU. vitals: 39.2C, HR 107, resps 19, BP 114/58, sat 96%. "awake but somnolent. cooperative, ill appearing....". not requiring vasopressors, continuing with IV fluids and trending lactate. COVID test pending. Discharged 2/23- 3 days in ICU and 5 days on the floor Diagnosis: PATIENT WITH SEVERE SEPSIS SECONDARY TO ACUTE PYELONEPHRITIS. WAS ADMITTED TO HOSPITAL HE HAD SEPSIS SECONDARY TO  PYELONEPHRITIS ,HAGMA WITH LACTIC ACIDOSIS , HE HAD PROFOUND INTRAVASCULAR VOLUME DEPLETION,ELEVATED LIVER ENZYMES PAROXYSMAL ATRIAL FIBRILLATION , THROMBOCYTOPENIA CHRONIC HYPERTENSION, DM TYPE 2 .PATIENT WITH LIFE ORGAN SYSTEM THREATENING CONDITION WHICH PATIENT WAS AT HIGH RISK OF DECOMPENSATION .EMPHYSEMATPUS CYSTITIS MILD ADYNAMIC ILEUS. Unable to review chart notes from patient's stay at hospital. Nothing scanned in to chart.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Intra-abdominal fluid collection, Lactic acidosis, Metabolic acidosis, Pyelonephritis, Sepsis
Clinical narrative: Narrative:  2-16-2021 admitted with sepsis, pyelonephritis and "HAGMA with lactic acidosis". WBC 2.8K, AST 332, ALT 196, T bili 1.8, gap 1.8, Lactic acidosis" but no value seen on note. CT abd shows bilateral perinephric stranding and fluid. and mild adynamic ileus. admitted to ICU. vitals: 39.2C, HR 107, resps 19, BP 114/58, sat 96%. "awake but somnolent. cooperative, ill appearing....". not requiring vasopressors, continuing with IV fluids and trending lactate. COVID test pending. Discharged 2/23- 3 days in ICU and 5 days on the floor Diagnosis: PATIENT WITH SEVERE SEPSIS SECONDARY TO ACUTE PYELONEPHRITIS. WAS ADMITTED TO HOSPITAL HE HAD SEPSIS SECONDARY TO  PYELONEPHRITIS ,HAGMA WITH LACTIC ACIDOSIS , HE HAD PROFOUND INTRAVASCULAR VOLUME DEPLETION,ELEVATED LIVER ENZYMES PAROXYSMAL ATRIAL FIBRILLATION , THROMBOCYTOPENIA CHRONIC HYPERTENSION, DM TYPE 2 .PATIENT WITH LIFE ORGAN SYSTEM THREATENING CONDITION WHICH PATIENT WAS AT HIGH RISK OF DECOMPENSATION .EMPHYSEMATPUS CYSTITIS MILD ADYNAMIC ILEUS. Unable to review chart notes from patient's stay at hospital. Nothing scanned in to chart.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Somnolence, Thrombocytopenia, Type 2 diabetes mellitus, White blood cell count decreased
Clinical narrative: Narrative:  2-16-2021 admitted with sepsis, pyelonephritis and "HAGMA with lactic acidosis". WBC 2.8K, AST 332, ALT 196, T bili 1.8, gap 1.8, Lactic acidosis" but no value seen on note. CT abd shows bilateral perinephric stranding and fluid. and mild adynamic ileus. admitted to ICU. vitals: 39.2C, HR 107, resps 19, BP 114/58, sat 96%. "awake but somnolent. cooperative, ill appearing....". not requiring vasopressors, continuing with IV fluids and trending lactate. COVID test pending. Discharged 2/23- 3 days in ICU and 5 days on the floor Diagnosis: PATIENT WITH SEVERE SEPSIS SECONDARY TO ACUTE PYELONEPHRITIS. WAS ADMITTED TO HOSPITAL HE HAD SEPSIS SECONDARY TO  PYELONEPHRITIS ,HAGMA WITH LACTIC ACIDOSIS , HE HAD PROFOUND INTRAVASCULAR VOLUME DEPLETION,ELEVATED LIVER ENZYMES PAROXYSMAL ATRIAL FIBRILLATION , THROMBOCYTOPENIA CHRONIC HYPERTENSION, DM TYPE 2 .PATIENT WITH LIFE ORGAN SYSTEM THREATENING CONDITION WHICH PATIENT WAS AT HIGH RISK OF DECOMPENSATION .EMPHYSEMATPUS CYSTITIS MILD ADYNAMIC ILEUS. Unable to review chart notes from patient's stay at hospital. Nothing scanned in to chart.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Asymptomatic COVID-19, Mental disorder, SARS-CoV-2 test positive
Clinical narrative: Narrative: hospitalization not related to covid - Mental health, no covid sx
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, COVID-19, Nausea, SARS-CoV-2 test positive, Vomiting
Clinical narrative: Narrative: Pt presented to the ED on 6/2/2021 c/o mid upper Abd pain and n/v. PT States she has not been able to keep anything down x1 week. reports h/o gastroparesis. Per lab testing pt. was covid positive. Pt was hydrated with IV bolus of NS X2 and given promethazine ivpb x 2 doses. Pt was hydrated with IV bolus of NSX 2 and given promethazine ivpb x doses. Pt had previously received both doses of Moderna covid vaccine on 3/31/21 and 4/26/21. Approximately timed. Pt was discharged from the ED with instructions same day. Not deemed a serious infection requring admission, although pt was threating to leave AMA if not allowed to leave once feeling better.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Adverse drug reaction, Pharyngitis
Clinical narrative: Narrative: A 73yo male with PMH of PUD, Pancreatic Cyst, HTN, Depression, Hepatitis, Cervical Radiculopathy, Episodic Opioid Dependence, Neck Pain, Low Back Pain, OA, DM and Gout He received his first Covid-19 vaccine per protocol on January 28, 2021 AM and the second dose on February 18, 2021 AM Chief of Ambulatory Care reported the patient with a historical ADR of Pharyngitis, which started two days post the second vaccine and resolved after few days.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative: Patient received Moderna COVID vaccine #1 on 4/12/21. This was the first time she had ever been seen at our facility. She then had a date of death recorded as 5/9/21. There are no notes or scanned records to indicate what happened from the time of vaccine to her death. No autopsy report available. Time from vaccine to death is 27 days.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Blood magnesium normal, Blood thyroid stimulating hormone normal, Bundle branch block right, Catheterisation cardiac abnormal, Chest pain
Clinical narrative: Narrative: 80 yo male with hx of diverticulosis, T2DM, esophageal stricture, HTN, BPH, GERD, hx of afib, coronary arteriosclerosis presented to the ED for chest pain on 3/19/2021, about 4 weeks after his last covid-19 vaccine. This event was reported since the event occurs within 42 days of the last dose of covid-19 vaccine. Per records, chest pain started after dinner, around his chest and radiated to his R arm. Pt was given aspirin 324mg PO enroute to the emergency. Pt denied any discomfort upon arrival to the ED. Hospital records stated no prior dx of CAD. However facility records show hx of coronary arteriosclerosis. EKG showed RBBB, no ST elevation or depression. Pt was admitted for monitoring and was discharged the next day (3/20/2021). On 4/9/2021, pt was scheduled for cath and was found to have 75% blockage to the LAD, pt was later scheduled for a DES.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Coronary artery occlusion, Electrocardiogram abnormal, Metabolic function test normal, Pain, Pain in extremity
Clinical narrative: Narrative: 80 yo male with hx of diverticulosis, T2DM, esophageal stricture, HTN, BPH, GERD, hx of afib, coronary arteriosclerosis presented to the ED for chest pain on 3/19/2021, about 4 weeks after his last covid-19 vaccine. This event was reported since the event occurs within 42 days of the last dose of covid-19 vaccine. Per records, chest pain started after dinner, around his chest and radiated to his R arm. Pt was given aspirin 324mg PO enroute to the emergency. Pt denied any discomfort upon arrival to the ED. Hospital records stated no prior dx of CAD. However facility records show hx of coronary arteriosclerosis. EKG showed RBBB, no ST elevation or depression. Pt was admitted for monitoring and was discharged the next day (3/20/2021). On 4/9/2021, pt was scheduled for cath and was found to have 75% blockage to the LAD, pt was later scheduled for a DES.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Angiopathy, Colitis ischaemic
Clinical narrative: Narrative: Patient, a 74-year-old male, received first COVID-19 vaccine dose on 02/09/21 (Lot# 031M20A, Exp Date: 08/05/2021) and received the second dose on 03/09/21 (Lot# 026A21A, Exp Date: 08/26/2021). On 05/13/21, patient reported having recent episode of ischemic colitis 2 weeks following his second COVID vaccine. Given new agent under EUA, will report finding for review. However, ischemic colitis appears to be due to vascular issues.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Atrial fibrillation, Chest pain, Death, General physical health deterioration
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient was 82 y.o. MALE with PMH of CKD stage 3, CHF, Dementia, schizophrenia, Afib, Depression, COPD, prostate cancer, Parkinsonism disease, CAD, Psychosis, Memory Loss, lower GI hemorrhage, Orthostatic Hypotension . Patient was resident of LTC with dementia and parkinsonism. Since last few months patient was residing in long term care and his health was declining. Jan 4th note says patient had chest pain, A.fib with RVR alternating with slow ventricular response with worsened weakness causing further impairment in mobility(wheelchair bound) and decline in functional abilities. Per last note from health and Rehab stated that patient passed away on 5.18. There was no further details on cause of death.
Age: 83.0
Sex: M
Vaccine: COVID19
Symptoms: Loss of personal independence in daily activities, Mobility decreased, Wheelchair user
Clinical narrative: Narrative: Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. Patient was 82 y.o. MALE with PMH of CKD stage 3, CHF, Dementia, schizophrenia, Afib, Depression, COPD, prostate cancer, Parkinsonism disease, CAD, Psychosis, Memory Loss, lower GI hemorrhage, Orthostatic Hypotension . Patient was resident of LTC with dementia and parkinsonism. Since last few months patient was residing in long term care and his health was declining. Jan 4th note says patient had chest pain, A.fib with RVR alternating with slow ventricular response with worsened weakness causing further impairment in mobility(wheelchair bound) and decline in functional abilities. Per last note from health and Rehab stated that patient passed away on 5.18. There was no further details on cause of death.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Akathisia, Computerised tomogram head normal, Hypoaesthesia, Laboratory test normal, Limb discomfort
Clinical narrative: Narrative:  Pt is a 40 y/o female with PMH significant for migraines and vestibular neuronitis who received the Jassen Covid vaccine on 4/10/2021. Provider contacted pt on 4/16/2021 regarding J&J vaccine pause. Pt reported she had the vaccine in her L arm and her LUE/LLE have been "numb" one hour after vaccine was administered. Numbness on left side was persistent and when trying to sleep, left side felt heavy but otherwise no motor symptoms, diplopia, or dysarthria. Pt was instructed to go to the ER and call medical facility after evaluation. Per Emergency Summary 4/20/2021, vital signs were completely stable and labs were normal at baseline. CT scans of the head revealed no intracranial abnormalities. Final diagnoses was motor restlessness. Pt was discharged home to f/u with PCP for further assessment and possible work-up. Upon chart review, no other noted s/sx or worsening of sxs related to COVID-19 vaccination.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Narrative: A 67yo male with PMH of Memory Loss, Depression, Shoulder Pain, Patellofemoral Stress Syndrome, Glaucoma, OSA, PTSD, Nuclear Sclerosis, Presbyopia, Low Back Pain, Knee pain He received Covid-19 vaccine first dose on February 21 PM and second dose on March 14, 2021 AM. On March 17, 2021 he was reported by the documenting attending physician with a historical ADR of Left Axillary Lymphadenopathy post the second Covid-19 vaccine in Lt arm.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Narrative:  Patient experiencing new onset Headache on left side of head. Reviewed Sign and symptoms of blood blot. Patient sought emergency care. Patient is currently on birth control.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Dizziness, Musculoskeletal stiffness, Peripheral coldness
Clinical narrative: Narrative: Slight mid abdominal pain 4/14, lessening. 4/15 light headedness; fingers cold/stiff
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain
Clinical narrative: Narrative:  Pain in the Armpit
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain
Clinical narrative: Narrative: Nausea and Distal soreness
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram cerebral, Areflexia, Asthenia, Cerebral ischaemia, Cervical spinal stenosis
Clinical narrative: Patient attributes left upper arm weakness to the second dose of his  COVID-19 vaccine administration on 2 16/21. Patient visited emergency  department (ED) on 4/5/21 complaining of weakness in left upper extremity  (LUE); unable to adduct or flex left shoulder beyond 15 degrees. ED noted that he  has equal grip strength bilaterally and able to raise shoulders equally. Patient  reports weakness is affecting his ADLs (including driving). Neurology assessed  patient on 5/17/21 for LUE weakness. Reportedly, he had no issues with the first  or second doses of the Pfizer COVID-19 mRNA vaccine except LUE weakness.  Some dull, constant pain of mild severity noted in left shoulder. Neurology also  noted his left shoulder active range of motion is only 15 degrees of abduction but  has full passive ROM. Strength was decreased in L shoulder abduction and flexion  as well as flexion at the elbow. There was moderate left biceps atrophy as  compared to right. L biceps reflex was absent. There is bilateral hand intrinsic  muscle atrophy of the ulnar muscles and swan-neck changes deformities  particularly of digits 4 and 5. There is no loss of sensation in the C5-6 dermatomal  distributions. Sensory exam shows decreased vibration and proprioception at the  toes as well as reflexes were diminished or absent on the left upper extremity.  MRI of brain did show some degenerative changes around C3. Concern for C5 6  radiculopathy; however difficult for unifying diagnosis per neurology.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Decreased vibratory sense, Diffusion-weighted brain MRI normal, Finger deformity, Hyporeflexia, Impaired driving ability
Clinical narrative: Patient attributes left upper arm weakness to the second dose of his  COVID-19 vaccine administration on 2 16/21. Patient visited emergency  department (ED) on 4/5/21 complaining of weakness in left upper extremity  (LUE); unable to adduct or flex left shoulder beyond 15 degrees. ED noted that he  has equal grip strength bilaterally and able to raise shoulders equally. Patient  reports weakness is affecting his ADLs (including driving). Neurology assessed  patient on 5/17/21 for LUE weakness. Reportedly, he had no issues with the first  or second doses of the Pfizer COVID-19 mRNA vaccine except LUE weakness.  Some dull, constant pain of mild severity noted in left shoulder. Neurology also  noted his left shoulder active range of motion is only 15 degrees of abduction but  has full passive ROM. Strength was decreased in L shoulder abduction and flexion  as well as flexion at the elbow. There was moderate left biceps atrophy as  compared to right. L biceps reflex was absent. There is bilateral hand intrinsic  muscle atrophy of the ulnar muscles and swan-neck changes deformities  particularly of digits 4 and 5. There is no loss of sensation in the C5-6 dermatomal  distributions. Sensory exam shows decreased vibration and proprioception at the  toes as well as reflexes were diminished or absent on the left upper extremity.  MRI of brain did show some degenerative changes around C3. Concern for C5 6  radiculopathy; however difficult for unifying diagnosis per neurology.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Injected limb mobility decreased, Injection site pain, Injection site reaction, Intervertebral disc degeneration, Ischaemic demyelination
Clinical narrative: Patient attributes left upper arm weakness to the second dose of his  COVID-19 vaccine administration on 2 16/21. Patient visited emergency  department (ED) on 4/5/21 complaining of weakness in left upper extremity  (LUE); unable to adduct or flex left shoulder beyond 15 degrees. ED noted that he  has equal grip strength bilaterally and able to raise shoulders equally. Patient  reports weakness is affecting his ADLs (including driving). Neurology assessed  patient on 5/17/21 for LUE weakness. Reportedly, he had no issues with the first  or second doses of the Pfizer COVID-19 mRNA vaccine except LUE weakness.  Some dull, constant pain of mild severity noted in left shoulder. Neurology also  noted his left shoulder active range of motion is only 15 degrees of abduction but  has full passive ROM. Strength was decreased in L shoulder abduction and flexion  as well as flexion at the elbow. There was moderate left biceps atrophy as  compared to right. L biceps reflex was absent. There is bilateral hand intrinsic  muscle atrophy of the ulnar muscles and swan-neck changes deformities  particularly of digits 4 and 5. There is no loss of sensation in the C5-6 dermatomal  distributions. Sensory exam shows decreased vibration and proprioception at the  toes as well as reflexes were diminished or absent on the left upper extremity.  MRI of brain did show some degenerative changes around C3. Concern for C5 6  radiculopathy; however difficult for unifying diagnosis per neurology.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Joint range of motion decreased, Loss of personal independence in daily activities, Loss of proprioception, Magnetic resonance imaging head abnormal, Muscle atrophy
Clinical narrative: Patient attributes left upper arm weakness to the second dose of his  COVID-19 vaccine administration on 2 16/21. Patient visited emergency  department (ED) on 4/5/21 complaining of weakness in left upper extremity  (LUE); unable to adduct or flex left shoulder beyond 15 degrees. ED noted that he  has equal grip strength bilaterally and able to raise shoulders equally. Patient  reports weakness is affecting his ADLs (including driving). Neurology assessed  patient on 5/17/21 for LUE weakness. Reportedly, he had no issues with the first  or second doses of the Pfizer COVID-19 mRNA vaccine except LUE weakness.  Some dull, constant pain of mild severity noted in left shoulder. Neurology also  noted his left shoulder active range of motion is only 15 degrees of abduction but  has full passive ROM. Strength was decreased in L shoulder abduction and flexion  as well as flexion at the elbow. There was moderate left biceps atrophy as  compared to right. L biceps reflex was absent. There is bilateral hand intrinsic  muscle atrophy of the ulnar muscles and swan-neck changes deformities  particularly of digits 4 and 5. There is no loss of sensation in the C5-6 dermatomal  distributions. Sensory exam shows decreased vibration and proprioception at the  toes as well as reflexes were diminished or absent on the left upper extremity.  MRI of brain did show some degenerative changes around C3. Concern for C5 6  radiculopathy; however difficult for unifying diagnosis per neurology.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Muscular weakness
Clinical narrative: Patient attributes left upper arm weakness to the second dose of his  COVID-19 vaccine administration on 2 16/21. Patient visited emergency  department (ED) on 4/5/21 complaining of weakness in left upper extremity  (LUE); unable to adduct or flex left shoulder beyond 15 degrees. ED noted that he  has equal grip strength bilaterally and able to raise shoulders equally. Patient  reports weakness is affecting his ADLs (including driving). Neurology assessed  patient on 5/17/21 for LUE weakness. Reportedly, he had no issues with the first  or second doses of the Pfizer COVID-19 mRNA vaccine except LUE weakness.  Some dull, constant pain of mild severity noted in left shoulder. Neurology also  noted his left shoulder active range of motion is only 15 degrees of abduction but  has full passive ROM. Strength was decreased in L shoulder abduction and flexion  as well as flexion at the elbow. There was moderate left biceps atrophy as  compared to right. L biceps reflex was absent. There is bilateral hand intrinsic  muscle atrophy of the ulnar muscles and swan-neck changes deformities  particularly of digits 4 and 5. There is no loss of sensation in the C5-6 dermatomal  distributions. Sensory exam shows decreased vibration and proprioception at the  toes as well as reflexes were diminished or absent on the left upper extremity.  MRI of brain did show some degenerative changes around C3. Concern for C5 6  radiculopathy; however difficult for unifying diagnosis per neurology.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  DEATH FOLLOWING 1 DOSE OF COVID VACCINE 02/12/2021 COVID vaccine dose #1 03/05/2021 Patient died at hospital (no records provided or reason given) Patient did not have reaction immediately following vaccine, did not have prior infection with COVID. Patient was seen in ED a few days prior to receiving covid vaccination (2/8-2/9) and was sent home with possible pneumonia, advised to follow up as outpatient. Received most of his medical care through other sources, saw his PCP once per year, in April. Likely that vaccine did not contribute to death, but was combination of advanced age (72 y/o) and comorbidities.
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Abdominal discomfort, Abdominal pain, Diarrhoea, Flatulence, Peripheral swelling
Clinical narrative: Narrative: Patient reported after receiving the 2nd Moderna dose experienced  symptoms of abdominal pain/ burning sensation, loose stools, and gas. Additionally reported leg swelling; no other information was documented in the EMR regarding duration of symptoms or interventions.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Antithrombin III decreased, Cerebral venous sinus thrombosis, Coagulation factor V level abnormal, Coagulopathy, Computerised tomogram
Clinical narrative: Narrative:  The patient received his Janssen Vaccine at facility on April 10th and then on April 30th he presents to the private Hospital w/ acute stroke symptoms. In reviewing the information from hospital they determine it was a sagittal sinus thrombus (venous thrombus). He is eventually found to have coagulopathy issues - low antithrombin III and abnormal factor V leiden. He transferred to another facility 4-30-21 and developed a worsening of his stroke symptoms. Repeat imaging determined his initial venous infarction progressed to a hemorrhagic conversion. He also developed bilateral DVT clots and a spontaneous pneumothorax.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis, Haemorrhagic transformation stroke, Imaging procedure abnormal, Infarction, Magnetic resonance imaging
Clinical narrative: Narrative:  The patient received his Janssen Vaccine at facility on April 10th and then on April 30th he presents to the private Hospital w/ acute stroke symptoms. In reviewing the information from hospital they determine it was a sagittal sinus thrombus (venous thrombus). He is eventually found to have coagulopathy issues - low antithrombin III and abnormal factor V leiden. He transferred to another facility 4-30-21 and developed a worsening of his stroke symptoms. Repeat imaging determined his initial venous infarction progressed to a hemorrhagic conversion. He also developed bilateral DVT clots and a spontaneous pneumothorax.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Neurological symptom, Pneumothorax spontaneous, Superior sagittal sinus thrombosis
Clinical narrative: Narrative:  The patient received his Janssen Vaccine at facility on April 10th and then on April 30th he presents to the private Hospital w/ acute stroke symptoms. In reviewing the information from hospital they determine it was a sagittal sinus thrombus (venous thrombus). He is eventually found to have coagulopathy issues - low antithrombin III and abnormal factor V leiden. He transferred to another facility 4-30-21 and developed a worsening of his stroke symptoms. Repeat imaging determined his initial venous infarction progressed to a hemorrhagic conversion. He also developed bilateral DVT clots and a spontaneous pneumothorax.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  Pt had both covid-19 vaccines on 4/16/21 & 5/14/21. Per CPRS noted pt died on 5/26/2021. No information available on nature of pt's death happened outpatient. Pt did not have comorbid diagnosis. Pt did have diagnosis of depression since 2019 & was a transgender (female at birth) & hx of hand surgery. Not clear if death related to covid vaccine or not.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event
Clinical narrative: Narrative:  Patient stated he is doing okay
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Exposure to SARS-CoV-2, Headache, Hypertension, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series completion 01/04 COVID vaccine dose #1 01/25 COVID vaccine dose #2 03/02 ED visit for headache x 3 days, treated for HTN and HA resolved 05/27 Tested for COVID due to exposure to wife who is positive for COVID, COVID test positive 06/05 Clinically resolved, no symptoms
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Pancreatitis acute, SARS-CoV-2 test positive
Clinical narrative: Narrative: this is being documented as a patient was admitted for acute pancreatitis after being fully vaccinated and found to be covid positive. Although the pancreatitis is not thought to be associated with COVID or the vaccine, and we have no evidence of prior infection, we are submitting this report because of the unexcludable possibility that previous or current COVID contributed to this pancreatitis admission.
Age: 60.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site rash
Clinical narrative: Narrative:  Patient presented for shingrex vaccine on 11/18/2020. reports a rash from the injection in the area where the vaccine was administered. A rash is a common side effect with the Shingrix vaccine, "erythema at injection site (38% to 39%), swelling at injection site (23% to 31%). "Per provider: " ASSESSMENT: 1. Probable drug reaction to Shingrix vaccine based on timing and rash."
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Malaise, Pain in extremity, Ultrasound Doppler normal
Clinical narrative: Narrative:  Pt is a 51 y/o female who received the Janssen Covid vaccine on 4/10/2021. Provider contacted patient for post vaccine f/u on 4/16/2021. Pt reported acute side effects including chills, headache, and malaise that lasted 1-2 days post vaccination which resolved completely. Pt also reported beginning on 4/14/2021, she noticed new pain in her right leg located behind the right knee and into the calf, no sxs noticed in left leg. Pt denied any chest pain, headache, visual changes, or other neurological sxs. Discussion of rare incidence of blood clots following Janssen Covid vaccine occurred and was recommended to go to ER for further evaluation. Per 4/16/2021 addendum, pt went to ER and received a negative doppler. Per chart review, no noted s/ sx related to COVID-19 vaccination.
Age: 47.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Anxiety, Blood pressure increased, Condition aggravated, Heart rate increased
Clinical narrative: Narrative:  Pt is a 45 y/o male with PMH significant for T2DM, panic attach, cognitive disorder, PTSD, psychosis, anxiety disorder, HTN, obesity, fibromyalgia, and low back pain. Pt received first Covid-19 vaccine dose on 3/10/2021. At the time, pt reported to physician 18 minutes after receiving vaccine feeling increased HR. Patient denied chest pain, dyspnea, weakness, flushing, abdominal pain, rash, or N/V/D. Vitals were checked which resulted: BP 153/103 HR 75 O2 Sat 98 % on RA. Pt endorsed that elevated BP and HR is normal when in an anxious state, pt also states he is worried about vaccine side effects. Repeat BPs were taken: BP 4:35 157/109 mmHg HR 75, 4:42 150/103 mmHg. Pt was observed for 40 minutes since reporting sxs and remained stable with no c/o. Pt was reexamined and cardiac/pulmonary examination remained normal. Pt received his second Covid-19 vaccine dose on 3/31/2021. Per chart review, no noted s/sx related to COVID-19 post 2nd administered dose.
Age: 61.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: Narrative: Pt was given a Moderna COVID-19 vaccination at Facility 1/30/2021. Per immunization registry information, he received a J&J vaccination on 5/22 at outside pharmacy. Pharmacy notified. Unknow if patient had any adverse reaction to vaccine as second vaccine was administered outside the facility.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Death, Diarrhoea, General physical health deterioration, Vomiting
Clinical narrative: Narrative:  74 y.o. male patient who received dose #1 of the Moderna COVID vaccine (Lot #031L20A, expiration 7/22/21) on 2/8/21. Primary Care Provider was notified of patient's death, which occurred in the patient's home around 20:03 on 2/20/2021. The patient's wife stated that patient had been functionally declining and weak. He also had a few episodes of vomiting and diarrhea but no blood in stool or in vomit. Per patient's wife, they did not plan to do an autopsy. Per PCP, possible cause of death includes right renal cell cancer, COPD with other associated co-morbidities. Renal ultrasound on 1/6/21 found "solid-appearing 1.8 cm mass at the lower pole the right kidney, suspicious for a primary neoplasm such as RCC." Patient followed with urology but declined any further workup. Reaction classified as severe as death occurred following vaccination.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Dizziness, Hot flush
Clinical narrative: Narrative:  8 yo female who presents to the ER for evaluation of possible allergic reaction after her 2nd Moderna COVID vaccine. Pt reports she had her second vaccine approximately 15 minutes before coming to the ER and started to  feel dizzy/lightheaded, have severe hot flashes and chest pain. Pt reports she is having severe "hot flashes" and pain in her chest. She did not have this issue with the first vaccine. Required treatment with IV benydral, pepcid, medrol and IV  fluids
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  Patient was not previously COVID-19 positive and did not have any predisposing factors(PMH, allergies, etc.) for experiencing an adverse drug event. The ADR did not occur at the time of the administration of the vaccine nor was there an ADR that occurred between the observation period and the date of death. PMH significant for sleep apnea, htn, morbid obesity, carcinoma of colon, seizure disorder. Pt was 74 years of age. No information available regarding cause of death, recent illnesses or hospitalizations available.
Age: 43.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Narrative:
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Narrative:
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Death, Gastrointestinal haemorrhage
Clinical narrative: Narrative:  85 y.o. male patient who received dose #1 of the Moderna COVID vaccine (Lot #013L20A exp 7/8/21) on 1/20/21. Patient was admitted to a hospital on 1/22/21 for an acute GI bleed (taking apixaban). The patient's wife notified the agency that the patient passed on 1/25/21. Agency has requested records from outside hospital but yet to be received. Reaction classified as severe as death occurred following vaccination.
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  88 y.o. male who received dose #1 of the Moderna COVID vaccine (Lot #024M20A, exp 8/3/21) on 2/18/21. Past medical history of Alzheimer's dementia, hyperlipidemia, BPH, and vit D deficiency. Patient presented to emergency department on 2/5/21 with sepsis secondary to aspiration pneumonia. He had a decline in functional status during previous week. He was unable to feed himself, walk, and only spoke 1-2 words at a time. Antibiotics discontinued due to goals of care. Family opt for comfort care. Patient was transferred to CLC hospice team on 2/12/2021. Patient passed on 3/1/21 @ 0930. Reaction classified as severe as death occurred following vaccination.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Myalgia, Pyrexia
Clinical narrative: Headache, Myalgia, Fever, chills Narrative:
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chest pain, Cough, Diarrhoea, Fatigue
Clinical narrative: Narrative:  COVID infection after COVID vaccine completion 03/12 COVID vaccine (dose 1 of 1) 03/15 pt reports dry hacking cough started 05/24 pt calls PCP report "he is feeling tired. He has had a dry hacking cough since 3/15.21. He feel as though it is related to the Covid Vaccine. He also states that he has multiple boils in his back that bleeds." 05/28 PCP visit: "Pt has a open ulcer in that scalpular region which is 2x3cm in size and looks fresh which he says is because of the COVID vaccine, pt has been having oozing pus with blood from it for 6 weeks and denies any picking at this point. It looks dry on my exam though. The surrounding is indurated. Skin looks normal around. Pt has dry cough and malaise since getting the vaccine and has no HF exacerbating symptoms. Pt at the end of the visit shows me the home kits which was positive for COVID." COVID test positive 05/29 Pt reports mild productive cough, diarrhea resolving, low grade fever, runny nose, myalgia 05/30 Pt reports new onset chest pain, did not seek care in ED as advised